TJX Companies Currently Down Seven Consecutive Days, on Track for Longest Losing Streak Since September 2021 — Data Talk
TJX Companies Inc (TJX) is currently at $88.12, down $1.04 or 1.17%
--Would be lowest close since Aug. 15, 2023, when it closed at $85.77
--Currently down seven consecutive days; down 5.84% over this period
--Longest losing streak since Sept. 13, 2021, when it fell for 12 straight trading days
--Worst seven day stretch since the seven days ending Sept. 27, 2022, when it fell 6.33%
--Down 4.71% month-to-date; on pace for worst month since Feb. 2023, when it fell 6.43%
--Up 10.7% year-to-date
--Down 5.84% from its all-time closing high of $93.59 on Sept. 14, 2023
--Up 46.11% from 52 weeks ago (Sept. 26, 2022), when it closed at $60.31
--Down 5.84% from its 52-week closing high of $93.59 on Sept. 14, 2023
--Up 46.11% from its 52-week closing low of $60.31 on Sept. 26, 2022
--Traded as low as $88.10; lowest intraday level since Aug. 25, 2023, when it hit $87.81
--Down 1.18% at today's intraday low
All data as of 3:10:34 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 25, 2023 15:28 ET (19:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm